CAJ | 학술논문

目的探讨复方丹参滴丸对糖尿病肾病(DN)患者血同型半胱氨酸(hcy)及肾功能指标的影响.方法将86例DN患者采用随机数字表法分为观察组与对照组,每组各43例,对照组患者进行常规控制血糖、调脂及降血压治疗,观察组在对照组基础上采用口服复方丹参滴丸治疗,比较两组患者的血同型半胱氨酸水平及肾功能相关指标指标.结果观察组治疗4周后患者hcy[(16.79±1.69)mmol/L vs(18.13±1.68)mmol/L]、治疗8周后[(14.53±1.82)mmol/L vs(17.83±1.62)mmol/L]、治疗16周[(12.70±1.71)mmol/L vs(17.54±1.19) mmol/L]后的hcy水平均显著低于对照组同期水平,P＜ 0.001;观察组患者治疗4周血清肌酐(SCr)[(135.90±28.13)μmol/L vs(138.16±28.46)μmol/L]、治疗8周[(131.69±25.79)μmol/L vs(138.22±24.19)μmol/L]及治疗16周[(126.9±26.9)μmol/L vs(136.97±23.80)μmol/L]的血清肌酐显著低于对照组同期,P＜ 0.001,观察组患者治疗4周[(48.37±11.68) ml/min vs(46.36±12.19) ml/min]、治疗8周[(50.46±12.80)ml/min vs(46.50±13.18)ml/min]及治疗16周后[(53.60±14.18)ml/min vs(46.62±13.79)ml/min]肌酐清除率(CCr)显著低于对照组同期,P＜0.001,观察组患者治疗8周[(10.28±6.30)mmol/L vs(11.20±6.34) mmol/L]、治疗16周[(968 ±4.16) mmol/L vs(11.28±6.14) mmol/L]的BUN水平显著低于对照组同期水平,P＜0.05.结论复方丹参滴丸可有效降低DN患者的血同型半胱氨酸水平,改善肾功能.
목적 탐토복방단삼적환대당뇨병신병(DN)환자혈동형반광안산(hcy)급신공능지표적영향.방법 장86례DN환자채용수궤수자표법분위관찰조여대조조,매조각43례,대조조환자진행상규공제혈당、조지급강혈압치료,관찰조재대조조기출상채용구복복방단삼적환치료,비교량조환자적혈동형반광안산수평급신공능상관지표지표.결과 관찰조치료4주후환자hcy[(16.79±1.69)mmol/L vs(18.13±1.68)mmol/L]、치료8주후[(14.53±1.82)mmol/L vs(17.83±1.62)mmol/L]、치료16주[(12.70±1.71)mmol/L vs(17.54±1.19) mmol/L]후적hcy수평균현저저우대조조동기수평,P＜ 0.001;관찰조환자치료4주혈청기항(SCr)[(135.90±28.13)μmol/L vs(138.16±28.46)μmol/L]、치료8주[(131.69±25.79)μmol/L vs(138.22±24.19)μmol/L]급치료16주[(126.9±26.9)μmol/L vs(136.97±23.80)μmol/L]적혈청기항현저저우대조조동기,P＜ 0.001,관찰조환자치료4주[(48.37±11.68) ml/min vs(46.36±12.19) ml/min]、치료8주[(50.46±12.80)ml/min vs(46.50±13.18)ml/min]급치료16주후[(53.60±14.18)ml/min vs(46.62±13.79)ml/min]기항청제솔(CCr)현저저우대조조동기,P＜0.001,관찰조환자치료8주[(10.28±6.30)mmol/L vs(11.20±6.34) mmol/L]、치료16주[(968 ±4.16) mmol/L vs(11.28±6.14) mmol/L]적BUN수평현저저우대조조동기수평,P＜0.05.결론 복방단삼적환가유효강저DN환자적혈동형반광안산수평,개선신공능.
Objective To explore the impact of CSDP on blood homocysteine and renal function indicators in patients with diabetic nephropathy.Methods 86 patients with DN were randomly divided into an observation group and a control group,43cases for each group.Routinely,the blood glucose was controlled,the lipid was regulated,and the blood pressure was lowered in the control group; in addition,CSDP was orally taken by the observaiton group.The blood homocysteine levels and renal function related indicators were compared between the two groups.Results 4,8,and 16 weeks after the treatment,the hcy level [(16.79±1.69) mmol/L vs.(18.13±1.68)mmol/L,(14.53±1.82)mmol/L vs.(17.83±1.62) mmol/L,and (12.70±1.71) mmol/L vs.(17.54±1.19)mmol/L] and the serum creatinine (SCr) level [(126.9 ± 26.9) μmol/L vs.(136.97 ± 23.80) μmol/L,(131.69 ± 25.79)μmol/L vs.(138.22 ± 24.19)μmol/L,and (126.9 ± 26.9μmol/ L vs.(136.97 ± 23.80)μmol/L] were much lower and the creatinine clearance (CCr) [(48.37 ± 1 1.68) ml/min vs.(46.36 ± 12.19) ml/min,(50.46 ± 12.80) ml/min vs.(46.50 ± 13.18) ml/min,and (53.60 ± 14.18) ml/min vs.(46.62 ± 13.79) ml/min] was significantly higher in the observation group than in the control group (P ＜0.001).8 and 16 weeks after the treatment,the BUN level was significantly lower in the observation group than in the control group [(10.28 ± 6.30) mmol/L vs.(11.20 ± 6.34) mmol/L] and (9.68 ± 4.16) mmol/L vs.(11.28 ± 6.14) mmol/L,P ＜0.05].Conclusions CSDP could effectively lower blood homocysteine level and improve kidney function in DN patients.